Avanos Medical agrees to acquire Diros Technology, RF pain management portfolio strengthened

AVANOS MEDICAL, INC.

Deal includes all outstanding shares of Diros Technology; financial terms not disclosed.
Financed via existing credit facility and available cash; expected to close Q3 2023.
Diros is a Toronto-based manufacturer of radiofrequency ablation products for chronic pain.
Avanos expects the acquisition to be immediately accretive to revenue, gross margins, operating margins, and EPS.
Diros' RF Trident technology complements Avanos' existing COOLIEF Cooled Radiofrequency product line.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.